Innovative solutions to
keep your project on course

Strategic Advice

Horizontal strategic planning across a drug development program can determine logical next steps and rational decision making.  Instead of focusing on a single study, it is critical to consider how that study complements prior data and influences future decisions in a program.

Nuventra approaches strategic advice for your program based on therapeutic class characteristics, individual aspects of the asset (formulation, route of administration, etc.), current FDA expectations, target patient population, and disease indication.

We build in steps to increase the valuation of your asset, de-risk certain characteristics of the asset based on your exit strategy, or address known therapeutic class or indication-specific issues to enhance your negotiation position with investors, partners, board members, and FDA/EMA.

Our pharmacokinetic consultants and clinical pharmacology consultants apply their experience from prior drug programs as well as current interactions with regulatory agencies to determine logical next steps in rational drug development.

Our Strategic Planning Services:

  • Complete NDA/BLA/ANDA due diligence
  • Full-service NDA/BLA/ANDA support
  • Interpretation of preclinical or early human data as a guide for next steps in clinical pharmacology programs
  • DDI waiver justifications
  • Pediatric study and PREA guidance
  • In vitro/in vivo transporter and DDI study guidance
  • Proactive risk management planning to identify and minimize development challenges
  • Review of clinical pharmacology data/decisions that impact late phase studies
  • Strategic planning for regulatory interactions associated with and without clinical pharmacology data
  • Interpretation of industry guidance documents for individual clinical pharmacology development programs
  • International trial advice and due diligence in support of expanding studies internationally

 

Explore Our Blog

Key Hurdles in Immuno-Oncology

Immuno-oncology is an exciting but challenging subspecialty that falls underneath the umbrella of oncology research and development. Unlike more traditional…

Read More

Programs to Promote Drug Development for Rare Diseases

Until the early 1980s, developing therapeutics to treat rare diseases was most often a money-losing endeavor due to high cost…

Read More

FDA Commissioner Emphasizes the Importance of Modeling and Simulation to Increase Efficiency and Reduce Costs in Drug Development

Dr. Scott Gottlieb, FDA Commissioner, delivered a speech to the Regulatory Affairs Professional Society Conference on September 11, 2017 highlighting the importance…

Read More